Thomas Muller

Summary

Country: Germany

Publications

  1. ncbi Allergic and nonallergic delayed infusion reactions during natalizumab therapy
    Kerstin Hellwig
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Arch Neurol 65:656-8. 2008
  2. ncbi Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Clin Neuropharmacol 30:101-6. 2007
  3. ncbi Is levodopa toxic?
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    J Neurol 251:VI/44-6. 2004
  4. ncbi Efficacy of budipine and placebo in untreated patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 112:1015-23. 2005
  5. ncbi Role of homocysteine in the treatment of Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Rev Neurother 8:957-67. 2008
  6. ncbi Antiapoptotic effects of budipine
    T Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Bochum, Germany
    J Neural Transm 111:1365-73. 2004
  7. ncbi Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial
    Thomas Muller
    Department of Neurology, St Josef Hospital Bochum, Ruhr University Bochum, Germany
    Psychosom Med 66:538-47. 2004
  8. ncbi Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Clin Neuropharmacol 31:134-40. 2008
  9. ncbi Diagnostic aspects of early Parkinson's disease
    Thomas Muller
    Dept of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    J Neurol 253:IV29-31. 2006
  10. ncbi Apomorphine delays simple reaction time in Parkinsonian patients
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Parkinsonism Relat Disord 8:357-60. 2002

Collaborators

Detail Information

Publications83

  1. ncbi Allergic and nonallergic delayed infusion reactions during natalizumab therapy
    Kerstin Hellwig
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Arch Neurol 65:656-8. 2008
    ..Delayed infusion reactions resembling serum sickness-type reactions (type III reaction) are commonly reported in other monoclonal antibody therapies (eg, infliximab and rituximab), but are not described yet for natalizumab...
  2. ncbi Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Clin Neuropharmacol 30:101-6. 2007
    ..These lower 5-HT levels reduce the hypothalamic function and, via the corticotropin axis, the subsequent peripheral cortisol release. Thus, levodopa-induced cortisol decrease may be related to PD progression...
  3. ncbi Is levodopa toxic?
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    J Neurol 251:VI/44-6. 2004
    ..e. folic acid administration in the case of levodopa-associated homocysteine elevation...
  4. ncbi Efficacy of budipine and placebo in untreated patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 112:1015-23. 2005
    ..These outcomes may result from improved non dopaminergic neurotransmission due to budipine. Placebo caused better results of dopamine sensitive tests, since placebo may release endogenous dopamine...
  5. ncbi Role of homocysteine in the treatment of Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Rev Neurother 8:957-67. 2008
    ..They have a structure similar to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine or its ion 1-methyl-4-phenylpyridinium, both of which are known to induce PD-like motor symptoms...
  6. ncbi Antiapoptotic effects of budipine
    T Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Bochum, Germany
    J Neural Transm 111:1365-73. 2004
    ..Our results suggest, that budipine administration provides an antiapoptotic environment and slows neuronal apoptotic and inflammatory mediated loss of neurons...
  7. ncbi Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial
    Thomas Muller
    Department of Neurology, St Josef Hospital Bochum, Ruhr University Bochum, Germany
    Psychosom Med 66:538-47. 2004
    ..To investigate efficacy and safety of St. John's wort (SJW) LI 160 in somatoform disorders...
  8. ncbi Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Clin Neuropharmacol 31:134-40. 2008
    ..This antiacid scenario may support a better muscle function with a positive impact on muscle excitability and contractibility...
  9. ncbi Diagnostic aspects of early Parkinson's disease
    Thomas Muller
    Dept of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    J Neurol 253:IV29-31. 2006
    ..It will also support the concept of a clinically effective pharmacological intervention on a disease process, which is also more and more demanded by the health authorities for drug approval...
  10. ncbi Apomorphine delays simple reaction time in Parkinsonian patients
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Parkinsonism Relat Disord 8:357-60. 2002
    ..Parkinsonian patients have difficulty in the preparation and execution of movements, which translate into delayed performance of simple reaction time (SRT) paradigms...
  11. ncbi Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Arch Neurol 61:657-60. 2004
    ..Levodopa metabolism via catechol O-methyltransferase increases levels of the neurotoxin homocysteine, which induces an axonal-accentuated degeneration in sensory peripheral nerves in vitro...
  12. ncbi Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Acta Neurol Scand 109:348-54. 2004
    ..Previous long-term dopaminergic substitution may cause a certain tolerance to this phenomenon...
  13. ncbi Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Mov Disord 21:332-6. 2006
    ..Our study shows a more stable LD plasma behavior during LCE intake and accordingly a better effect on motor symptoms according to rating outcomes and motor test results to a lesser extent...
  14. ncbi Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Clin Neuropharmacol 28:238-40. 2005
    ....
  15. ncbi Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells
    Thomas Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neurol Res 30:417-9. 2008
    ..Clinically, our findings support an early start of long-term treatment with selegiline in view of the various neurotoxin hypotheses and mechanisms of neuronal death in chronic neurodegenerative disorders...
  16. ncbi Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    J Neural Transm 114:1023-6. 2007
    ..Treatment of dyskinesia was looked upon as not satisfactory, fractionating of levodopa dose was used as first choice therapeutic option of dyskinesia...
  17. ncbi Acute levodopa administration reduces cortisol release in patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 114:347-50. 2007
    ..This hypothetically causes an reduced 5-HT content in neurons projecting to the hypothalamic structures, which are involved in the partial 5-HT dependent central regulation of peripheral cortisol release...
  18. ncbi Levodopa, motor fluctuations and dyskinesia in Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56 44791 Bochum, Germany
    Expert Opin Pharmacother 7:1715-30. 2006
    ..It also gives an overview of existing and potential future treatment-strategies for the management of these troublesome treatment complications that affect motor behaviour in PD patients...
  19. ncbi [Cost and quality aspects in the treatment of Parkinson's disease]
    Thomas Muller
    Neurologische Klinik im St Josef Hospital, Ruhr Universitat Bochum
    Z Arztl Fortbild Qualitatssich 100:291-5. 2006
    ..The Parkinsonian patient should benefit from the scientific progress in the treatment of PD. This will improve quality of life and at least decrease the indirect costs of PD on the long term...
  20. ncbi Entacapone improves complex movement performance in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    J Clin Neurosci 14:424-8. 2007
    ..A possible strategy to prolong plasma metabolism of Levodopa/Carbidopa (LD/CD) is Entacapone addition (EN), which improves impaired motor behaviour in patients with Parkinson's disease (PD)...
  21. ncbi Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients
    Thomas Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Gudrunstr 56, 44791, Bochum, Germany
    Eur J Clin Pharmacol 62:447-50. 2006
    ..A further therapeutic alternative is inhibition of catechol-O-methyltransfrase (COMT) on a regular basis, when levodopa/DDI treatment is performed...
  22. ncbi Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease
    T Muller
    St Josef Hospital, Department of Neurology, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 114:1457-62. 2007
    ..LD/CD/EN was superior to LD/CD regarding the attention related components of line tracing probably due to a hypothetically increased dopamine occurrence at the prefrontal cortex, which guides human behaviour...
  23. ncbi Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Neurosci Lett 422:119-22. 2007
    ..This might additionally have caused the significant faster GH release during exercise...
  24. ncbi Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Clin Neuropharmacol 29:61-7. 2006
    ....
  25. ncbi Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 113:1441-8. 2006
    ..An impact of EN on 3-OMD levels appeared. A possibly augmented LD absorption and a prolonged LD metabolism after EN supplementation may contribute to a more continuous LD delivery to the brain...
  26. ncbi Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    CNS Drugs 18:105-11. 2004
    ..This study was conducted to determine the effect of an inpatient setting (a specialised Parkinson's disease clinic) on drug therapy costs and patient symptoms...
  27. ncbi Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Berlin, Germany
    Mov Disord 23:1458-61. 2008
    ..This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself...
  28. ncbi Quantification of the dopaminergic response in Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Parkinsonism Relat Disord 8:181-6. 2002
    ....
  29. ncbi 3-OMD and homocysteine plasma levels in parkinsonian patients
    Th Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Federal Republic of Germany
    J Neural Transm 109:175-9. 2002
    ..52, p = 0.0006) correlated to 3-OMD. Homocysteine induces vascular disease. Previous studies showed an increase of ischaemic heart- and cerebrovascular disease in treated parkinsonian patients...
  30. ncbi Entacapone
    Thomas Muller
    St Joseph Hospital Berlin Weissensee, Department of Neurology, Berlin, Germany
    Expert Opin Drug Metab Toxicol 6:983-93. 2010
    ..These plasma fluctuations support alternating stimulation of striatal postsynaptic dopamine receptors and thus onset of motor complications. They are significant components for the quality of treatment of PD patients...
  31. ncbi Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University of Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Clin Neuropharmacol 28:274-6. 2005
    ....
  32. ncbi Progress of visual dysfunction in Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University of Bochum, 44791 Bochum, Germany
    Acta Neurol Scand 105:256-60. 2002
    ..002) and analogously (ii) scored intensity of PD (P=0.002). A relation between computed differences of FMT error scores and rated activities of daily living appeared. Deterioration of color vision progresses in PD...
  33. ncbi Drug treatment of non-motor symptoms in Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Opin Pharmacother 3:381-8. 2002
    ..Nevertheless, this review tries to provide a survey of possible therapeutic options for the treatment of the symptoms of Parkinson's disease other the dopamine-sensitive motor features...
  34. ncbi Delay of simple reaction time after levodopa intake
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    Clin Neurophysiol 112:2133-7. 2001
    ..To date, no trial considered putative effects of dopaminergic substitution on SRT performance in PP...
  35. ncbi Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, D 44791, Bochum, Germany
    Neurosci Lett 308:54-6. 2001
    ..SAH with its short half-life did not differ. Levodopa/DDI long-term treatment contributes to altered levels of substrates of the O-methylation cycle in PP...
  36. ncbi Non-dopaminergic drug treatment of Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Opin Pharmacother 2:557-72. 2001
    ....
  37. ncbi Tolcapone increases maximum concentration of levodopa
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Federal Republic of Germany
    J Neural Transm 107:113-9. 2000
    ..We found a significant increase of Cmax of levodopa after the addition of tolcapone. This may represent one cause for the occurrence of dyskinesia previously early in the course of treatment with tolcapone...
  38. ncbi R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University of Bochum, Germany
    J Neurol Sci 164:158-62. 1999
    ..We conclude, that central accumulation of R-NMSAL, which is neurotoxic to dopaminergic nigrostriatal neurons, is not due to elevated synthesis of R-SAL and/or S-SAL in PD...
  39. ncbi Dopaminergic substitution in Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Opin Pharmacother 3:1393-403. 2002
    ....
  40. ncbi Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    NeuroRehabilitation 18:271-5. 2003
    ..There is a move towards treatment of Parkinson's disease (PD) patients in specialized units, however, data on the outcome and on daily antiparkinsonian drug costs are rare...
  41. ncbi [Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122]
    Th Muller
    Neurologische Universitätsklinik im St Josef Hospital, Ruhr Universitat Bochum, Gudrunstrasse 56, 44791 Bochum
    Nervenarzt 74:726-7. 2003
  42. ncbi Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients
    Thomas Muller
    Department of Neurology, Ruhr University of Bochum, St Josef Hospital, Gudrunstrasse 56, Bochum 44791, Germany
    J Neurol Sci 213:61-5. 2003
    ..016) lower in patients with better peg insertion outcome. A significant (Spearman R=0.47, p=0.012) correlation between peg insertion results and the FMT error scores appeared. Motor impairment influences FMT error scores in PD patients...
  43. ncbi Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease
    Th Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 110:603-9. 2003
    ..07). We suggest diagnostic acute challenge test performance with LD as first- and A as second choice due to better tolerability and valuation in combination with repeated scoring procedures to improve sensitivity and specifity...
  44. ncbi Role of intraspinal steroid application in patients with multiple sclerosis
    Thomas Muller
    Department of Neurology, St Joseph Hospital, Berlin Weissensee, Gartenstrasse 1, 13088 Berlin, Germany
    Expert Rev Neurother 9:1279-87. 2009
    ....
  45. ncbi Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Germany
    Neurosci Lett 341:201-4. 2003
    ..48, P=0.008) better improvement of FMT performance compared with placebo. Our results indicate a moderate beneficial effect of oral CoQ(10) supplementation in PD patients...
  46. ncbi Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    Neurosci Lett 339:25-8. 2003
    ..Since peg insertion depends on more complex movements and thus more dopamine dependent cognitive processes, it improved after application of the indirect dopaminomimetic substance amantadine...
  47. ncbi CPI-1189. Centaur
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Curr Opin Investig Drugs 3:1763-7. 2002
    ....
  48. ncbi Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Gartenstr 1, 13 088 Berlin, Germany
    J Neurol Neurosurg Psychiatry 81:747-53. 2010
    ..This may result from an exercise induced increase in endogenous dopamine synthesis. As a result, beneficial effects on movement and reactivity may occur...
  49. ncbi Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Gartenstr 1, 13088 Berlin, Germany
    Naunyn Schmiedebergs Arch Pharmacol 383:627-33. 2011
    ..Measurements of homocysteine should consider acute repeated levodopa/DDI applications, as homocysteine and metabolically related 3-O-methyldopa accumulate due to their long plasma half-life in contrast to short-living levodopa...
  50. ncbi Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease
    Alexander Storch
    Department of Neurology, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Arch Neurol 64:938-44. 2007
    ..Coenzyme Q(10) (CoQ(10)) is an electron acceptor bridging mitochondrial complexes I and II/III and a potent antioxidant that consistently partially recovers the function of dopaminergic neurons...
  51. ncbi Peripheral COMT inhibition prevents levodopa associated homocysteine increase
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Gartenstr 1, 13088, Berlin, Germany
    J Neural Transm 116:1253-6. 2009
    ..Therefore, peripheral COMT inhibition may have a beneficial effect on putative, controversially debated components of homocysteine-related progression of PD...
  52. ncbi Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD
    Jürgen Andrich
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Mov Disord 19:226-8. 2004
    ..Because the protein Huntingtin interacts with the homocysteine metabolism modulating enzyme cystathionine beta-synthase, we hypothesize that homocysteine promotes neurodegeneration in HD...
  53. ncbi Betamethasone-related acute alterations of microtubule-associated proteins in the fetal sheep brain are reversible and independent of age during the last one-third of gestation
    Iwa Antonow Schlorke
    Department of Neurology, Friedrich Schiller University, Jena, Germany
    Am J Obstet Gynecol 196:553.e1-6. 2007
    ..The purpose of this study was to examine whether glucocorticoid effects on neuronal cytoskeleton, which we have shown previously at 0.87 gestation when the hypothalamo-pituitary-adrenal axis matures, are age-dependent and reversible...
  54. ncbi Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital, Ruhr University Bochum, Bochum, Germany
    J Neural Transm 115:851-5. 2008
    ..Since cortisol improves muscle function, the lack of increase in maximal grip strength following LD administration during exercise may contribute to reduced exercise capacity, which is reported by PD patients...
  55. ncbi Complex movement behaviour and progression of Huntington's disease
    Jürgen Andrich
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Neurosci Lett 416:272-4. 2007
    ..We conclude, that instrumental assessment of complex movement sequences is an additional simple method to follow impairment in HD patients in addition to clinical rating...
  56. ncbi Motor complications, levodopa metabolism and progression of Parkinson's disease
    Thomas Muller
    St Joseph Hospital Berlin Weissensee, Department of Neurology, Gartenstr 1, 13088 Berlin, Germany
    Expert Opin Drug Metab Toxicol 7:847-55. 2011
    ..This may slow the progression of PD and delay the onset of MC, both of which represent unmet needs in the treatment of PD patients...
  57. ncbi A transcriptional network coordinately determines transmitter and peptidergic fate in the dorsal spinal cord
    Dominique Bröhl
    Department of Neuroscience, Max Delbrück Centrum for Molecular Medicine, Berlin, Germany
    Dev Biol 322:381-93. 2008
    ..We conclude that a transcriptional network operates in maturing dorsal horn neurons that coordinately determines transmitter and peptidergic fate...
  58. ncbi Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Gartenstr 1, 13088 Berlin, Germany
    Neurosci Lett 521:37-9. 2012
    ..Cysteine decrease may result from an up regulation of GSH synthesis to encounter augmented appearance of free radicals associated with LD turnover via mitochondrial monoaminooxidase...
  59. ncbi Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel
    Thomas Muller
    Department of Neurology, St Joseph Hospital, Berlin Weissensee, Gartenstr 1, 13088, Berlin, Germany
    J Neural Transm 118:1329-33. 2011
    ..7) correlation between LD and 3-OMD. thcys ascent was observed in relation with the onset of atherosclerosis, non-motor symptoms and polyneuropathy in PD patients in the long term...
  60. ncbi Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Germany
    Mov Disord 24:1339-43. 2009
    ..91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients...
  61. ncbi Exercise improves efficacy of levodopa in patients with Parkinson's disease
    Siegfried Muhlack
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Bochum 44791, Germany
    Mov Disord 22:427-30. 2007
    ..Moderate exercise increases clinical efficacy of LD...
  62. ncbi Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Berlin, Germany
    Mov Disord 26:543-6. 2011
    ..Cys-Gly decay may result from the alternative transformation of glutathione to its oxidized form glutathione dissulfide as consequence of free radical scavenging...
  63. ncbi Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms
    Kerstin Hellwig
    Department of Neurology, St, Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    BMC Neurol 4:18. 2004
    ..There are controversial results on the efficacy of the abandoned, intrathecal predominant methylprednisolone application in multiple sclerosis (MS) in contrast to the proven effectiveness in intractable postherpetic neuralgia...
  64. ncbi Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen
    Horst Przuntek
    Department of Neurology, Ruhr University of Bochum, Gudrunstrass 56, 44791 Bochum, Germany
    Arch Neurol 59:803-6. 2002
    ..Previous studies have demonstrated the therapeutic efficacy of budipine on motor symptoms in insufficiently treated patients with Parkinson disease...
  65. ncbi Mutation analysis of the neurofilament M gene in Parkinson's disease
    Rejko Kruger
    Department of Neurology, Neurodegeneration Laboratory, University of Tubingen, Hoppe Seyler Strasse 3, D 72076, Tubingen, Germany
    Neurosci Lett 351:125-9. 2003
    ..However, rare variants of the NF-M gene may act as susceptibility factors for PD and functional analyses of the identified variations are warranted to decipher possible mechanisms in neurodegeneration...
  66. ncbi Assessment of simple movements and progression of Huntington's disease
    Jürgen Andrich
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, D 44791 Bochum, Germany
    J Neurol Neurosurg Psychiatry 78:405-7. 2007
    ..Instrumental test results significantly correlated with both UHDRS scores at each assessment. Assessment of simple movement sequences is an additional simple method to follow impairment in patients with HD in addition to clinical rating...
  67. ncbi Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease
    Siegfried Muhlack
    Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Neurosci Lett 363:284-7. 2004
    ..The maximum plasma levodopa concentration did not differ (ANCOVA: F(1.19) = 1.17, P = 0.29). Long-term levodopa administration results in an increased levodopa plasma bioavailability in PD patients...
  68. ncbi Levodopa availability improves with progression of Parkinson's disease
    Dirk Woitalla
    Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstr. 56, 44791 Bochum, Germany
    J Neurol 253:1221-6. 2006
    ..This may result from deteriorated peripheral activity of levodopa metabolising enzymes or an increasing enteric dysfunction with subsequent better duodenal levodopa absorption or both...
  69. ncbi Diadochokinetic movements differ between patients with Parkinson's disease and controls
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin, Weissensee, Gartenstr 1, 13088 Berlin, Germany
    J Neural Transm 117:189-95. 2010
    ..This altered performance of diadochokinetic movements corresponds to the clinical motor symptoms of PD patients and differs from healthy controls...
  70. ncbi Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients
    Sören Peters
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neuroreport 14:809-12. 2003
    ..These findings warrant future consideration and further investigation of possible central inhibitory effects of dopaminergic therapy in functional imaging studies in PD...
  71. ncbi Cysteine elevation in levodopa-treated patients with Parkinson's disease
    Thomas Muller
    Department of Neurology, St Joseph Hospital Berlin Weissensee, Gartenstrasse 1, Berlin, Germany or
    Mov Disord 24:929-32. 2009
    ..The correlation outcomes support the view that LD/DCI intake may also increase cysteine...
  72. ncbi Are individuals with an eating disorder less sensitive to aesthetic flaws than healthy controls?
    Tanja Legenbauer
    Institute of Psychology, Department of Clinical Psychology and Psychotherapy, Johannes Gutenberg University Mainz, Mainz, Germany
    J Psychosom Res 65:87-95. 2008
    ..This study aimed to investigate whether the positive evaluation of other people's bodies is due to difficulties in the recognition of flaws in attractive features of others...
  73. ncbi Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany
    Can J Neurol Sci 29:73-7. 2002
    ..Future studies on the efficacy of antiparkinsonian drugs, using instrumental tasks for objective assessment, should consider long-term impact of antiparkinsonian drug therapy and associated cognitive efforts...
  74. ncbi Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion
    Birgit Meiler
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791 Bochum, Germany
    Mov Disord 23:145-6. 2008
    ..We have shown that a prior change to an oral levodopa monotherapy and a slow titration of duodenal levodopa infusion may be skipped and a direct switch to duodenal levodopa is a safe option...
  75. ncbi Deep brain stimulation improves performance of complex instrumental paradigms
    Gisa Ellrichmann
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Eur Neurol 60:32-6. 2008
    ....
  76. ncbi Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide
    Jens Reimer
    Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Germany
    Parkinsonism Relat Disord 9:115-6. 2002
    ....
  77. ncbi Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients
    Volker Hoffmann
    Department of Neurology, St. Josef-Hospital, Ruhr-University of Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    J Neurol Sci 211:81-4. 2003
    ..No serious side effects occurred. We conclude that repeated intrathecal TCA injection provides substantial benefit for progressive MS patients with predominantly spinal symptoms...
  78. ncbi Assessment of complex movements reflects dysfunction in Huntington's disease
    Carsten Saft
    Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany
    J Neurol 250:1469-74. 2003
    ..Therefore peg insertion particularly reflects executive dysfunction in early HD and additionally motor impairment in advanced HD...
  79. ncbi Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease
    Thorsten Schulte
    Department of Neurology, Ruhr University Bochum, St Josef Hospital, Bochum, Germany
    Neurosci Lett 326:70-2. 2002
    ..We found T in position -511 in the IL-1 beta gene more frequent in patients compared to controls (chi(2)=4.44, P=0.034). For the IL-1 alpha-889 polymorphism no significant difference between patients and controls was observed...
  80. ncbi Assessment of simple movements reflects impairment in Huntington's disease
    Carsten Saft
    Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Mov Disord 21:1208-12. 2006
    ..Results of our applied instrumental tool measure impaired movement performance, which is not specific for HD, but reflects the various methods assessed and the slowly evolving symptoms of the degenerative process in HD...
  81. ncbi Recovery of glucocorticoid-related loss of synaptic density in the fetal sheep brain at 0.75 of gestation
    Claudia Colberg
    Department of Neurology, Friedrich Schiller University, D-07740 Jena, Germany
    Neurosci Lett 364:130-4. 2004
    ..It was not accompanied by neuronal damage and was reversible within 24h. In conclusion, fetal betamethasone exposure induces a gestational age-dependent decrease of synaptic density that is transient and more severe in younger fetuses...
  82. ncbi Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics
    A Winkler
    Institute for Molecular Pharmacology, Berlin, Germany
    Alcohol 15:43-50. 1998
    ..The observed changes seem to be correlated with ethanol intake, because the elevated POMC mRNA amounts found in lymphocytes of alcoholics after admission to the hospital were already declining after the detoxification period...
  83. ncbi Betamethasone effects on fetal sheep cerebral blood flow are not dependent on maturation of cerebrovascular system and pituitary-adrenal axis
    Matthias Lohle
    Department of Neurology, Friedrich Schiller University, 07740 Jena, Germany
    J Physiol 564:575-88. 2005
    ..87 of gestation. We conclude that the cerebrovascular effects of antenatal glucocorticoids are independent of cerebrovascular maturation and preparturient increase in activity of the fetal pituitary-adrenal axis...